



Press release

GLSV co-finances Nabriva GmbH, an antibiotic research company spun off from Sandoz

Munich/Zug, 31 January 2006 – *Global Life Science Ventures (GLSV)* today announced the launch of Nabriva GmbH, a specialist antibiotic research and development company that has existed until now within Sandoz GmbH as the Vienna-based Antibiotic Research Institute (ABRI). GLSV is investing €6 million in a Series A financing round totalling €42 million, as part of a syndicate led by Nomura and also including Wellcome, HBM and Novartis Bioventures.

ABRI was originally founded in 2001 with the objective of discovering and developing new antibiotic compounds. With Sandoz's recent strategic re-orientation as the generics company within Novartis, it was decided to spin off ABRI and allow the late-preclinical stage company to develop outside of the Sandoz structure.

Nabriva will focus on the development of small molecule antibiotics for use in community and hospital infections. Nabriva has a strong pipeline of antibacterial drugs including three late preclinical projects and one product about to enter Phase 1 clinical trials. All the projects are based on families of small molecules with known antibiotic activity. Antibiotics form a major part of the anti-infectives market, the second most frequently prescribed class of drugs, representing 10% of the global pharmaceutical market. In 2004, the US antibiotics market was valued at \$15.4 billion.

Dr. Peter Reinisch, Partner at Global Life Science Ventures, commented: "Our decision to support Nabriva is based on the great promise of their proprietary compounds, addressing the huge anti-infectives market. With the increasing threat posed by resistant strains, Nabriva's pipeline has significant advantages over existing antibacterials. We believe that Nabriva and its strong research team have the potential to become a leading new player on the European biotechnology front."

About Global Life Science Ventures:

GLSV is a leading, independent venture capital fund focusing exclusively on the life sciences. With offices in Germany and Switzerland, GLSV is dedicated to supporting early-stage companies originating from universities, scientific institutions or industry, but also invests in selected later-stage companies, including buy-outs. The group currently advises and manages funds totalling more than €200 million. GLSV has now financed 29 innovative life science companies, twelve of which have completed an exit through IPO, trade sale or M&A. GLSV has built up a broadly diversified portfolio of companies in pharmaceuticals, diagnostics, medical devices, and biotechnology.

Global Life Science Ventures

Industry-born team – Proven track record – Global perspective

Germany

GLSV GmbH

Von-der-Tann-Str. 3

D – 80539 München

Tel. +49 (0)89 288 151 0

Fax +49 (0)89 288 151 30

www.glsv-vc.com

mailbox@glsv-vc.com

Switzerland

GLSV AG

Postplatz 1, P.O. 626

CH – 6301 Zug

Tel. +41 (0)41 727 19 40

Fax +41 (0)41 727 19 45

For additional information, please contact:

Rochat & Partners

Christophe Lamps / Jonathan Leighton

Tel. +41 22 718 37 46

Fax +41 22 786 54 58

E-mail: clamps@rochat-pr.ch / jonathan@rochat-pr.ch